Lisi SA

FII

Equity

ISIN FR0000050353 / Valor 494737

Euronext - Euronext Paris (2026-08-07)

EUR 67.20+1.66%

Lisi SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Lisi SA is a French industrial group that designs, manufactures and supplies engineered fastening and assembly components across aerospace, automotive and medical markets. The company’s product range includes precision fasteners, rivets, threaded inserts, locking systems and other joining solutions for aircraft and automotive manufacturers, as well as medical implants and instruments through its healthcare division. It serves original equipment manufacturers and tier‑one suppliers, combining metalworking and assembly capabilities with engineering and testing to meet sector-specific regulations and performance requirements, and operates a network of production and service sites internationally while being publicly traded in France.

Summarized from source with an LLMView SourceSector: Industrials

Headline results (FY 2025)

Revenue €1,747.9m (+8.7% vs restated 2024); EBITDA €261.5m (+42.5%) with a 15.0% EBITDA margin; EBIT €161.0m (+63.2%) and net income €139.7m (2.5x 2024). Earnings per share €3.06 (basic).

Quarter / growth detail

Q4 2025 revenue €436.7m (record quarter), up +4.0% year‑on‑year (like‑for‑like growth stronger); full‑year organic growth +11.5% at constant exchange rates and scope.

Division performance

LISI AEROSPACE: record revenue €1,191.1m (+15.6%), strong margin and EBIT improvement (current operating income €140.1m). LISI AUTOMOTIVE: revenue €558.5m (‑3.7%), but improved current operating margin to 5.0% and positive operating free cash flow.

Cash flow & investments

Cash flow from operations €198.3m (+28.3%); net industrial investments ~€99.9m; operating free cash flow €56.1m (positive in both divisions). Adjusted for FX conversion impact, divisions’ operating FCF ~€87m.

Balance sheet & leverage

Net financial debt reduced to €233.7m (from €488.5m), net debt/EBITDA ~0.9x (vs 2.3x in 2024), and equity strengthened — providing headroom versus banking covenants.

Sale of LISI MEDICAL

LISI MEDICAL was sold on October 31, 2025 for a net price of €270.4m; Lisi retained a 9.988% minority stake (valued ~€18.1m) and potential earn‑outs. The sale was accounted for under IFRS 5 and materially improved reported net debt and reported net income (discontinued operations contributed €76.4m).

Other items & shareholder return

Inclusion in the SBF 120 and CAC Mid 60 indices in Dec‑2025. The Board proposes a dividend of €0.46 per share for 2025 (up from €0.39 in 2024).

Outlook

Strong aerospace order book supports expected group growth in 2026; management targets continued improvement in key financial metrics (particularly current operating income) and positive free cash flow in 2026, assuming stable exchange rates and macro conditions.

Summarized from source with an LLMView Source

Key figures

40.9%1Y

197%3Y

126%5Y

Performance

39.1%1Y

33.2%3Y

34.0%5Y

Volatility